ECOR logo

electroCore, Inc. Stock Price

NasdaqCM:ECOR Community·US$38.0m Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 23 Fair Values set on narratives written by author

ECOR Share Price Performance

US$5.01
-2.94 (-36.98%)
80.1% undervalued intrinsic discount
US$25.20
Fair Value
US$5.01
-2.94 (-36.98%)
80.1% undervalued intrinsic discount
US$25.20
Fair Value
Price US$5.01
AnalystHighTarget US$25.20
AnalystConsensusTarget US$21.24
AnalystLowTarget US$12.00

ECOR Community Narratives

AnalystHighTarget·Updated
Fair Value US$25.2 80.1% undervalued intrinsic discount

Aging Population Will Expand gammaCore Adoption For Neuromodulation

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·Updated
Fair Value US$21.4 76.6% undervalued intrinsic discount

Chronic Disorder Trends Will Expand Noninvasive Neuromodulation Adoption

0users have liked this narrative
0users have commented on this narrative
9users have followed this narrative
AnalystLowTarget·Updated
Fair Value US$12 58.3% undervalued intrinsic discount

Slow VA Adoption Will Hinder Operations Yet Will Reveal Opportunity

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative

Recent ECOR News & Updates

It's Down 27% But electroCore, Inc. (NASDAQ:ECOR) Could Be Riskier Than It Looks

Aug 24
It's Down 27% But electroCore, Inc. (NASDAQ:ECOR) Could Be Riskier Than It Looks

Analysts Have Made A Financial Statement On electroCore, Inc.'s (NASDAQ:ECOR) Second-Quarter Report

Aug 09
Analysts Have Made A Financial Statement On electroCore, Inc.'s (NASDAQ:ECOR) Second-Quarter Report

Further Upside For electroCore, Inc. (NASDAQ:ECOR) Shares Could Introduce Price Risks After 43% Bounce

Jul 10
Further Upside For electroCore, Inc. (NASDAQ:ECOR) Shares Could Introduce Price Risks After 43% Bounce

electroCore, Inc. Key Details

US$27.7m

Revenue

US$4.0m

Cost of Revenue

US$23.7m

Gross Profit

US$36.9m

Other Expenses

-US$13.3m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.75
Gross Margin
85.52%
Net Profit Margin
-47.84%
Debt/Equity Ratio
0%

electroCore, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with high growth potential.

4 Risks
4 Rewards

About ECOR

Founded
2005
Employees
73
CEO
Daniel Goldberger
WebsiteView website
www.electrocore.com

electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions. In addition, the company offers TAC-STIM for human performance and gammaCore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.

Market Insight

Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading

U.S. Market Performance

  • 7 Days: 0.9%
  • 3 Months: 8.7%
  • 1 Year: 18.4%
  • Year to Date: 14.8%
The Healthcare sector gained 6.4% while the market remained flat over the last week. Meanwhile, the market is actually up 18% over the past year. Earnings are forecast to grow by 15% annually. Market details ›